Utilization and Treatment Costs of Tumor Necrosis Factor Inhibitors After the Introduction of Biosimilar Infliximab in the United States
Seoyoung C. Kim, Ameet Sarpatwari, Joan Landon, Rishi Desai
Topics & Concepts
BiosimilarMedicineInfliximabCitationFamily medicineLibrary scienceTumor necrosis factor alphaInternal medicineComputer scienceBiosimilars and Bioanalytical MethodsCAR-T cell therapy researchPharmaceutical studies and practices